ARTICLE | Company News
Chimerix, Merck deal
July 30, 2012 7:00 AM UTC
Chimerix granted Merck exclusive, worldwide rights to HIV candidate CMX157. Chimerix will receive $17.5 million up front and will be eligible for $151 million in milestones, plus royalties. The produ...